A study evaluated two low-level red light (LLRL) devices for myopia control, the Sky-n1201a and Future Vision, to determine their safety. Both devices were classified as Class 1 lasers, but their output exceeded the maximum permissible exposure (MPE) for photochemical and thermal damage, especially with larger pupils. The Sky-n1201a delivered 7.2–88.2 W/cm² retinal irradiance, with an MPE for photochemical damage of 0.55–7 seconds and thermal damage of 0.41–10 seconds for pupils 2–7 mm. The Future Vision had lower irradiance, with an MPE for photochemical damage of 50–625 seconds. Three minutes of continuous use of either device exceeded the MPE, risking retinal damage. The study highlights the need for further safety assessments before recommending LLRL therapy for children. Clinicians should exercise caution until safety standards are confirmed. The devices' parameters vary, and their safety depends on pupil size and exposure duration. While LLRL therapy shows promise in reducing myopia progression, its long-term safety remains uncertain.A study evaluated two low-level red light (LLRL) devices for myopia control, the Sky-n1201a and Future Vision, to determine their safety. Both devices were classified as Class 1 lasers, but their output exceeded the maximum permissible exposure (MPE) for photochemical and thermal damage, especially with larger pupils. The Sky-n1201a delivered 7.2–88.2 W/cm² retinal irradiance, with an MPE for photochemical damage of 0.55–7 seconds and thermal damage of 0.41–10 seconds for pupils 2–7 mm. The Future Vision had lower irradiance, with an MPE for photochemical damage of 50–625 seconds. Three minutes of continuous use of either device exceeded the MPE, risking retinal damage. The study highlights the need for further safety assessments before recommending LLRL therapy for children. Clinicians should exercise caution until safety standards are confirmed. The devices' parameters vary, and their safety depends on pupil size and exposure duration. While LLRL therapy shows promise in reducing myopia progression, its long-term safety remains uncertain.